- Home
- ERAS vs CHY Comparison
ERAS vs CHY Comparison
Compare ERAS & CHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ERAS | CHY |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 896.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ERAS | CHY |
|---|---|---|
| Price | $15.51 | $11.83 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $5.78 | N/A |
| AVG Volume (30 Days) | ★ 3.3M | 194.3K |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.11% |
| EPS Growth | ★ 16.87 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.01 | $9.00 |
| 52 Week High | $15.27 | $12.12 |
Technical Indicators
Market Signals| Indicator | ERAS | CHY |
|---|---|---|
| Relative Strength Index (RSI) | 79.90 | 47.01 |
| Support Level | $1.46 | $11.40 |
| Resistance Level | N/A | $12.05 |
| Average True Range (ATR) | 0.85 | 0.14 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 88.11 | 38.71 |
Price Performance
Historical ComparisonAbout ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.